Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $759.44, giving the company a market capitalization of 80.28B. It carries a P/E multiple of 18.07 and pays a dividend yield of 47.8%.
During the trading session on 2026-04-23, Regeneron(REGN) shares reached a daily high of $767.04 and a low of $747.26. At a current price of $759.44, the stock is +1.6% higher than the low and still -1.0% under the high.
Trading activity shows a volume of 469.27K, compared to an average daily volume of 642.61K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Regeneron Pharmaceuticals (REGN) announced on Thursday that the U.S. Food and Drug Administration (FDA) granted accelerated approval for its gene therapy Otarme...
Regeneron (REGN) Pharmaceuticals announced the U.S. Food and Drug Administration has granted accelerated approval for Otarmeni, the first gene therapy and secon...
Regeneron (REGN) reached a deal with the Trump administration to lower drug costs as it received approval for its gene therapy to treat a rare form of deafness,...
Analyst ratings
77%
of 31 ratingsMore REGN News
Advertisement Regeneron overview and recent performance snapshot Regeneron Pharmaceuticals (REGN) continues to attract investor attention as a large US biotec...
Regeneron Pharmaceuticals (NasdaqGS:REGN) reported positive Phase 2 results for lunsekimig, a bispecific antibody, in moderate to severe asthma and chronic rhin...
Key Points Moderna's innovative technology could help it establish itself as a leader in the vaccine market. Regeneron has an exciting lineup of candidates, i...
Regeneron (REGN) Pharmaceuticals announced detailed results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myast...
Earlier this month, Regeneron Pharmaceuticals and Sanofi announced that the European Commission approved Dupixent for moderate-to-severe chronic spontaneous urt...
The European Commission approved Dupixent as the first targeted treatment for moderate to severe chronic spontaneous urticaria in children aged 2 to 11 across t...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.